LORDS

How will the life sciences strategy affect businesses?

16 October 2017

The House of Lords Science and Technology Committee continues taking evidence for its inquiry into Life Sciences and the Industrial Strategy. Over three evidence sessions the Committee questions global leaders in pharmaceuticals GlaxoSmithKline (GSK) and AstraZeneca, as well as representatives of Small Medium Enterprises (SMEs) and healthcare regulatory and advice bodies.

Purpose of session

The Committee begins by questioning GSK and AstraZeneca and explores what contribution large pharmaceutical companies can make to the implementation of the strategy and the attractiveness of the UK as place for businesses to invest in life sciences.

In the second evidence session the Committee hears from Randox Laboratories, Inhealthcare and Matoke Holdings three UK based life science SMEs. They question the challenges smaller companies face in areas such as funding and innovation.

In the final evidence session, representatives from the National Institute for Health and Care Excellence (NICE) and Medicines and Healthcare Products Regulatory Agency (MHRA) are questioned on the possible impact of different regulations between the UK and the EU could have after Brexit and whether regulators should do more to aid the uptake of innovative products by the NHS.

Witnesses

Tuesday 17 October in Committee Room 4A, Palace of Westminster

At 10.10am

  • Dave Allen, Senior Vice President Respiratory Disease R&D, GSK
  • Menelas Pangalos, Executive Vice-President, Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca

At 11.00am

  • Bryn Sage, CEO, Inhealthcare Ltd
  • Mark Campbell CBE, Senior Manager, Randox Laboratories Ltd
  • Ian Staples, Chief Executive, Matoke Holdings Ltd

At 11.50am

  • Dr Ian Hudson, Chief Executive, Medicines and Healthcare Products Reulatory Agency (MHRA)
  • Sir Andrew Dillon, Chief Executive, National Institute for Health and Care Excellence (NICE)

Possible questions

Questions likely to be covered in the sessions include:

  • What is your experience of getting innovations in treatments and devices taken up by the NHS?
  • What is your experience of accessing different sources of funding to grow your company?
  • What are your overall impressions of the Life Sciences Industrial Strategy and to what extent were your organisations involved in its preparation?
  • Are there any aspects of regulation that are proving a block to the taking of science to innovation and commercialisation?

Further information

Image: iStockphoto

More news on: Parliament, government and politics, Parliament, Science and technology, Research and innovation, Science, Health services and medicine, House of Lords news, Lords news, Committee news

Share this page